Cargando…

Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphoma (CTCL) is the most frequently encountered type of skin lymphoma in humans. CTCL encompasses multiple variants, but the most common types are mycosis fungoides (MF) and Sezary syndrome (SS). While most cases of MF run a mild course over a period of many years, other subtypes...

Descripción completa

Detalles Bibliográficos
Autores principales: Ion, Alexandra, Popa, Iris Maria, Papagheorghe, Laura Maria Lucia, Lisievici, Cristina, Lupu, Mihai, Voiculescu, Vlad, Caruntu, Constantin, Boda, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086377/
https://www.ncbi.nlm.nih.gov/pubmed/27821903
http://dx.doi.org/10.1155/2016/9602472
_version_ 1782463727170224128
author Ion, Alexandra
Popa, Iris Maria
Papagheorghe, Laura Maria Lucia
Lisievici, Cristina
Lupu, Mihai
Voiculescu, Vlad
Caruntu, Constantin
Boda, Daniel
author_facet Ion, Alexandra
Popa, Iris Maria
Papagheorghe, Laura Maria Lucia
Lisievici, Cristina
Lupu, Mihai
Voiculescu, Vlad
Caruntu, Constantin
Boda, Daniel
author_sort Ion, Alexandra
collection PubMed
description Cutaneous T-cell lymphoma (CTCL) is the most frequently encountered type of skin lymphoma in humans. CTCL encompasses multiple variants, but the most common types are mycosis fungoides (MF) and Sezary syndrome (SS). While most cases of MF run a mild course over a period of many years, other subtypes of CTCL are very aggressive. The rapidly expanding fields of proteomics and genomics have not only helped increase knowledge concerning the carcinogenesis and tumor biology of CTCL but also led to the discovery of novel markers for targeted therapy. Although multiple biomarkers linked to CTCL have been known for a relatively long time (e.g., CD25, CD45, CD45RA, and CD45R0), compared to other cancers (lymphoma, melanoma, colon carcinoma, head and neck cancer, renal cancer, and cutaneous B-cell lymphoma), information about the antigenicity of CTCL remains relatively limited and no dependable protein marker for CTCL has been discovered. Considering the aggressive nature of some types of CTCL, it is necessary to identify circulating molecules that can help in the early diagnosis, differentiation from inflammatory skin diseases (psoriasis, nummular eczema), and aid in predicting the prognosis and evolution of this pathology. This review aims to bring together some of the information concerning protein markers linked to CTCL, in an effort to further the understanding of the convolute processes involved in this complex pathology.
format Online
Article
Text
id pubmed-5086377
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-50863772016-11-07 Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma Ion, Alexandra Popa, Iris Maria Papagheorghe, Laura Maria Lucia Lisievici, Cristina Lupu, Mihai Voiculescu, Vlad Caruntu, Constantin Boda, Daniel Dis Markers Review Article Cutaneous T-cell lymphoma (CTCL) is the most frequently encountered type of skin lymphoma in humans. CTCL encompasses multiple variants, but the most common types are mycosis fungoides (MF) and Sezary syndrome (SS). While most cases of MF run a mild course over a period of many years, other subtypes of CTCL are very aggressive. The rapidly expanding fields of proteomics and genomics have not only helped increase knowledge concerning the carcinogenesis and tumor biology of CTCL but also led to the discovery of novel markers for targeted therapy. Although multiple biomarkers linked to CTCL have been known for a relatively long time (e.g., CD25, CD45, CD45RA, and CD45R0), compared to other cancers (lymphoma, melanoma, colon carcinoma, head and neck cancer, renal cancer, and cutaneous B-cell lymphoma), information about the antigenicity of CTCL remains relatively limited and no dependable protein marker for CTCL has been discovered. Considering the aggressive nature of some types of CTCL, it is necessary to identify circulating molecules that can help in the early diagnosis, differentiation from inflammatory skin diseases (psoriasis, nummular eczema), and aid in predicting the prognosis and evolution of this pathology. This review aims to bring together some of the information concerning protein markers linked to CTCL, in an effort to further the understanding of the convolute processes involved in this complex pathology. Hindawi Publishing Corporation 2016 2016-10-16 /pmc/articles/PMC5086377/ /pubmed/27821903 http://dx.doi.org/10.1155/2016/9602472 Text en Copyright © 2016 Alexandra Ion et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Ion, Alexandra
Popa, Iris Maria
Papagheorghe, Laura Maria Lucia
Lisievici, Cristina
Lupu, Mihai
Voiculescu, Vlad
Caruntu, Constantin
Boda, Daniel
Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma
title Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma
title_full Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma
title_fullStr Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma
title_full_unstemmed Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma
title_short Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma
title_sort proteomic approaches to biomarker discovery in cutaneous t-cell lymphoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086377/
https://www.ncbi.nlm.nih.gov/pubmed/27821903
http://dx.doi.org/10.1155/2016/9602472
work_keys_str_mv AT ionalexandra proteomicapproachestobiomarkerdiscoveryincutaneoustcelllymphoma
AT popairismaria proteomicapproachestobiomarkerdiscoveryincutaneoustcelllymphoma
AT papagheorghelauramarialucia proteomicapproachestobiomarkerdiscoveryincutaneoustcelllymphoma
AT lisievicicristina proteomicapproachestobiomarkerdiscoveryincutaneoustcelllymphoma
AT lupumihai proteomicapproachestobiomarkerdiscoveryincutaneoustcelllymphoma
AT voiculescuvlad proteomicapproachestobiomarkerdiscoveryincutaneoustcelllymphoma
AT caruntuconstantin proteomicapproachestobiomarkerdiscoveryincutaneoustcelllymphoma
AT bodadaniel proteomicapproachestobiomarkerdiscoveryincutaneoustcelllymphoma